SynthesisInternational journal of molecular sciences2023
Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights.
Synthesis in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 67 citations in OpenAlex.
- Pilot Results of Masibambisane: Couples Motivational Interviewing with Mobile Breathalyzers to Address Unhealthy Drinking and Adherence to Antiretroviral Therapy in South Africa.AIDS and behavior · 2025Trial
- Trial
- Identifying Hazardous Alcohol Use in Primary Care: Concordance Between Phosphatidylethanol and Self-Reports.Annals of family medicine · 2026Article
- Reversible alterations of brain acetate metabolism associated with alcohol consumption.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Measurement of Central Nervous System-Related Biomarkers in Plasma of Burn Patients.Shock (Augusta, Ga.) · 2026Article
- Development and Optimization of an LC-MS/MS Method for Quantification of Phosphatidylethanol in Human Whole Blood.Journal of mass spectrometry : JMS · 2026Article
- Addressing Alcohol Use Disorder in Alcohol-Associated Liver Disease.Clinical and translational gastroenterology · 2026Review
- LC-MS/MS of PEth in whole blood: implementation in routine clinical chemistry.Practical laboratory medicine · 2026Article
- Examining Phosphatidylethanol (PEth) Formation Rates Within and Between Subjects in Ex Vivo Whole Blood.Drug testing and analysis · 2026Article
- Prevalence of Steatotic Liver Disease with Fibrosis and Diagnostic Screening Tools in Patients with Psoriasis.Acta dermato-venereologica · 2026Article
- Exploring Phosphatidylethanol Cutoffs for Self-Reported Unhealthy Alcohol Use: An International Multi-Site Analysis.Alcohol, clinical & experimental research · 2026Article
- Age and Sex Differences in Alcohol Withdrawal Syndrome.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- The global epidemiology of alcohol-associated liver disease.Hepatology communications · 2026Review
- Alcohol use disorder: an Australian perspective on screening, diagnosis, treatment and prevention.Internal medicine journal · 2026Review
- Measuring lifetime alcohol exposure: A scoping review and implications for translational research and alcohol-related harm.Addiction (Abingdon, England) · 2026Article
- The stealthy saboteur: hepatic steatosis and its erosion of APRI and FIB-4 accuracy.Frontiers in medicine · 2026Article
- The patterns of relapse and abstinence: using machine learning to identify a multidimensional signature of long-term outcome after inpatient alcohol withdrawal treatment.Frontiers in psychiatry · 2026Article
- Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults.BMJ medicine · 2026Review
- Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Neurotoxicity of Chronic Alcohol Exposure: Mechanistic Insights, Cellular Disruption, and Emerging Therapeutic Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Alcohol Use Disorders Identification Test (AUDIT) and its short form, the AUDIT-C, the main clinical instruments used to identify unhealthy drinking behaviors, are influenced by memory bias and under-reporting. In recent years, phosphatidylethanol (PEth) in blood has emerged as a marker of unhealthy alcohol use. This systematic review aims to investigate the molecular characteristics of PEth and summarize the last ten years of published literature and its use compared to structured questionnaires. A systematic search was performed, adhering to PRISMA guidelines, through "MeSH" and "free-text" protocols in the databases PubMed, SCOPUS, and Web of Science. The inclusion criteria were as follows: PEth was used for detecting unhealthy alcohol consumption in the general population and quantified in blood through liquid chromatography coupled to mass spectrometry, with full texts in the English language. Quality assessment was performed using the JBI critical appraisal checklist. Twelve papers were included (0.79% of total retrieved records), comprising nine cross-sectional studies and three cohort studies. All studies stratified alcohol exposure and quantified PEth 16:0/18:1 through liquid chromatography coupled to mass spectrometry (LC-MS) in liquid blood or dried blood spots (DBS) with lower limits of quantitation (LLOQ) ranging from 1.7 ng/mL to 20 ng/mL. A correlation between blood PEth level and the amount of alcohol ingested in the previous two weeks was generally observed. PEth interpretative cut-offs varied greatly among the included records, ranging from 4.2 ng/mL to 250 ng/mL, with sensitivity and specificity in the ranges of 58-100% and 64-100%, respectively. Although the biomarker seems promising, further research elucidating the variability in PEth formation and degradation, as well as the molecular mechanisms behind that variability, are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.